CSL (OTCMKTS:CSLLY) was upgraded by Macquarie from a “neutral” rating to an “outperform” rating in a report released on Tuesday, The Fly reports.
CSLLY has been the subject of several other reports. Citigroup raised shares of CSL from a “neutral” rating to a “buy” rating in a report on Wednesday, March 10th. The Goldman Sachs Group lowered shares of CSL from a “buy” rating to a “neutral” rating in a report on Thursday, February 18th. JPMorgan Chase & Co. lowered shares of CSL from an “overweight” rating to a “neutral” rating in a report on Wednesday, January 27th. Credit Suisse Group raised shares of CSL from a “neutral” rating to an “outperform” rating in a report on Tuesday, March 23rd. Finally, Zacks Investment Research downgraded shares of CSL from a “hold” rating to a “sell” rating in a research report on Tuesday, April 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. CSL currently has a consensus rating of “Hold” and an average price target of $119.00.
Shares of CSLLY stock traded up $0.81 during mid-day trading on Tuesday, reaching $105.17. The company’s stock had a trading volume of 50,415 shares, compared to its average volume of 56,835. The company’s 50 day simple moving average is $102.34 and its 200-day simple moving average is $106.41. CSL has a 12-month low of $91.04 and a 12-month high of $117.98. The company has a quick ratio of 1.37, a current ratio of 3.01 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $95.73 billion, a PE ratio of 45.53 and a beta of 0.59.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Featured Article: CAC 40 Index
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.